Acadian Asset Management LLC Sells 80,157 Shares of BioAtla, Inc. (NASDAQ:BCAB)

Acadian Asset Management LLC lowered its holdings in shares of BioAtla, Inc. (NASDAQ:BCAB) by 51.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 75,031 shares of the company’s stock after selling 80,157 shares during the period. Acadian Asset Management LLC owned about 0.16% of BioAtla worth $102,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Valmark Advisers Inc. acquired a new position in BioAtla during the second quarter worth about $34,000. Rinkey Investments acquired a new position in BioAtla during the 2nd quarter worth approximately $35,000. Price T Rowe Associates Inc. MD acquired a new position in BioAtla during the 1st quarter worth approximately $45,000. Virtu Financial LLC bought a new position in BioAtla in the 1st quarter valued at approximately $103,000. Finally, Pale Fire Capital SE boosted its position in BioAtla by 204.6% in the fourth quarter. Pale Fire Capital SE now owns 48,383 shares of the company’s stock valued at $119,000 after buying an additional 32,500 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of BioAtla in a report on Monday, September 16th.

BioAtla Price Performance

BioAtla stock opened at $1.72 on Friday. The business has a 50 day moving average of $1.73 and a 200-day moving average of $2.12. The company has a market capitalization of $82.76 million, a P/E ratio of -0.69 and a beta of 1.06. BioAtla, Inc. has a 1 year low of $1.14 and a 1 year high of $4.02.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. During the same quarter last year, the firm earned ($0.75) earnings per share. Equities analysts anticipate that BioAtla, Inc. will post -1.51 EPS for the current year.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.